Foundation Medicine teams with IMS on precision medicine service

Foundation Medicine ($FMI) and IMS Health ($IMS) have teamed up to offer a precision medicine service. The alliance brings together Foundation Medicine's cancer genomics database and IMS' real-world evidence platform, a combination the partners think can enable the effective use of more targeted therapies. "This collaboration with Foundation Medicine extends our Real-World Evidence platform, uniquely linking claims, EMR and biomarker data at the anonymous patient level to ... improve clinical development and commercialization strategies," IMS VP Jon Resnick said in a statement. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.